Comorbidities in multiple myeloma and implications on survival: A population‐based study
- 10 February 2021
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 106 (6) , 774-782
Abstract
High proportion of patients with multiple myeloma suffer from comorbidities which may alter clinical management. Therefore, our aims were to evaluate the prevalence of comorbidities and their impact on survival. We included patients diagnosed with multiple myeloma 1990‐2013 in Sweden and all diagnoses from each patient from 1985. A total of 13 656 patients with multiple myeloma were included in the study, thereof 7404 (54%) had comorbidity at diagnosis. The risk of death was increased for those with one comorbidity at diagnosis compared to those without any comorbidity (hazard ratio = 1.19; 95% confidence interval:1.14‐1.25); this risk was higher for those with two (1.38; 1.30‐1.47) and three or more comorbidities (1.72; 1.62‐1.83). Furthermore, the risk of death was increased in patients with prior history of cancer, arrhythmia, heart failure, diabetes mellitus, cerebrovascular disease, chronic lung disease, psychological disease, peptic ulcer, neurological disease, peripheral vascular disease, chronic kidney disease, dementia, and inflammatory bowel disease. This large study shows that over 50% of multiple myeloma patients have a comorbidity at diagnosis and survival decreased with increasing numbers of comorbidities. This emphasizes the importance of comorbidities when evaluating patients and deciding on treatment strategies for individuals with multiple myeloma.Keywords
This publication has 42 references indexed in Scilit:
- The impact of comorbidity on cancer survival: a reviewClinical Epidemiology, 2013
- Thrombosis is associated with inferior survival in multiple myelomaHaematologica, 2012
- Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortalityBritish Journal of Cancer, 2012
- Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007Circulation: Cardiovascular Quality and Outcomes, 2012
- Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity scoreBlood Cancer Journal, 2011
- The Influence of Comorbidities on Overall Survival Among Older Women Diagnosed With Breast CancerJNCI: Journal of the National Cancer Institute, 2011
- External review and validation of the Swedish national inpatient registerBMC Public Health, 2011
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003Journal of Clinical Oncology, 2007
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987